ARS Pharmaceuticals, Inc.
NASDAQ:SPRYBiotechnology
-$0.35 today
- Market cap
- $370.95M
- Beta
- 0.83
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$1.99
Volume 1.70M
Average 1.67M
SPRY Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
ARS Pharmaceuticals, Inc.NASDAQ: SPRY
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $4.34M rose 46.9% year over year, ahead of the -15.8% change in trailing-twelve-month research & development. Sequentially, it rose 25.9% from the prior quarter. Over 3 fiscal years it compounded at -10.5% a year.
Context
- Research & development amounted to 15.6% of revenue in FY2025, down 6.3 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +46.9% holds above the trailing-twelve-month pace of -15.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 13.18M USD
- Year-over-year change
- -32.7%
- 4-year CAGR
- -10.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.18M | -32.7% |
| FY2024 | 2024-12-31 | 19.58M | -3.4% |
| FY2023 | 2023-12-31 | 20.27M | +10.3% |
| FY2022 | 2022-12-31 | 18.38M | -9.4% |
| FY2021 | 2021-12-31 | 20.27M | — |
Research & Development vs competitors
How SPRY compares with its peers on the latest reported figures
- SPRY's LTM Mar 2026 research & development of $14.57M is the lowest of the 4 companies compared; the peer median is $32.2M.
- Its year-over-year change of -15.8% is the 3rd highest of 4, against a peer median of +26.3%.
- Research & development amounts to 14.7% of revenue for SPRY, versus a peer median of 20.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $72.56M | +54.7% | +49.8% | 20.1% | |
| LTM Mar 2026 | $32.2M | +26.3% | +14.1% | 10.2% | |
| LTM Mar 2026 | $16.04M | -18.6% | -0.6% | 31.9% | |
SPRYARS Pharmaceuticals, Inc. | LTM Mar 2026 | $14.57M | -15.8% | -10.5% | 14.7% |
| Peer median (excluding SPRY) | $32.2M | +26.3% | +14.1% | 20.1% | |
Competitors are the stored peer set for SPRY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.51M | 1.32M | 30K | 89.15M | 84.28M |
| Cost of Revenue | 213K | 17.12M | 0 | 20.56M | 20.42M |
| Gross Profit | 5.29M | (15.8M) | 30K | 68.59M | 63.86M |
| Gross Margin | 96.1% | -1200.9% | 100.0% | 76.9% | 75.8% |
| Research & Development | 20.27M | 18.38M | 20.27M | 19.58M | 13.18M |
| Selling, General & Admin | 4.69M | 18.66M | 47.28M | 0 | 230.12M |
| Operating Expenses | 24.75M | 19.71M | 67.55M | 71.68M | 243.3M |
| Depreciation & Amortization | 213K | 319K | 73K | 79K | 1.37M |
| EBITDA | (19.92M) | (34.36M) | (54.29M) | 8.37M | (167.41M) |
| EBITDA Margin | -361.9% | -2611.2% | -180973.3% | 9.4% | -198.6% |
| Operating Income | (19.45M) | (35.52M) | (67.52M) | (3.08M) | (179.45M) |
| Operating Margin | -353.3% | -2698.8% | -225066.7% | -3.5% | -212.9% |
| Interest Income | 800K | 0 | 0 | 0 | 10.67M |
| Interest Expense | 106K | 0 | 0 | 0 | 2.6M |
| Other Income / Expenses | (789K) | 834K | 13.16M | 11.37M | 8.07M |
| Income Before Tax | (20.24M) | (34.68M) | (54.37M) | 8.29M | (171.38M) |
| Pre-Tax Margin | -367.7% | -2635.4% | -181216.7% | 9.3% | -203.3% |
| Income Tax Expense | 0 | 0 | 0 | 288K | (80K) |
| Net Income | (20.24M) | (34.68M) | (54.37M) | 8M | (171.3M) |
| Net Margin | -367.7% | -2635.4% | -181216.7% | 9.0% | -203.3% |
| EPS (Basic) | (0.70) | (0.87) | (0.57) | 0.08 | (1.74) |
| EPS (Diluted) | (0.70) | (0.87) | (0.57) | 0.08 | (1.74) |
| Weighted Avg Shares | 28.87M | 39.96M | 95.22M | 96.94M | 98.57M |
| Weighted Avg Shares (Diluted) | 28.87M | 39.96M | 95.22M | 102.39M | 98.57M |
ARS Pharmaceuticals, Inc.
NASDAQ:SPRY
Intrinsic Alpha fair value
Locked
Current Price
$3.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.